

pCpGrich-mcs

A CpG-containing control plasmid

Catalog # pcprg-mcs

For research use only

Version 21F04-MM

PRODUCT INFORMATION

Content:

- 20 µg of pCpGrich-mcs plasmid provided as lyophilized DNA
- *E. coli* GT115 strain provided lyophilized on a paper disk
- 1 ml of Zeocin™ (100 mg/ml)

Storage and Stability:

- Products are shipped at room temperature.
- Lyophilized DNA is stable 1 year when stored at -20°C.
- Resuspended DNA is stable 6 months when stored at -20°C.
- Bacteria should be stored at -20°C and are stable up to 1 year.
- Store Zeocin™ at 4 °C or at -20 °C. The expiry date is specified on the product label.

Quality control:

Plasmid construct has been confirmed by restriction analysis and sequencing. Plasmid DNA was purified by ion exchange chromatography and lyophilized. Viability of the lyophilized bacteria upon resuspension has been verified.

GENERAL PRODUCT USE

InvivoGen has developed a new family of plasmids that are completely devoid of CpG dinucleotides. These plasmids yield high levels of transgene expression both *in vitro* and *in vivo*, and in contrast to CMV-based plasmids allow sustained expression *in vivo*.

pCpGfree plasmids contain elements that naturally lack CpG dinucleotides, were modified to remove all CpGs, or entirely synthesized such as genes encoding selectable markers or reporters. pCpGfree plasmids represent valuable tools to study the effects of CpGs on gene expression *in vivo* and *in vitro*, using cell lines expressing TLR9, as well as their effects on the innate and acquired immune systems.

pCpGrich-mcs is a CpG-containing control plasmid. The CpG-free version of the murine CMV enhancer, human EF-1α promoter, ori R6K gamma, bacterial EM2K promoter and Zeocin™ resistance gene have been replaced by their wild-type (wt) counterparts. The pCpGrich-mcs plasmid contains 88 CpG dinucleotides.

PLASMID FEATURES

Elements for expression in *E. coli*

- R6K gamma ori (wt): This origin of replication is activated by the R6K specific initiator protein π, encoded by the *pir* gene¹.
- EM7 is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*.
- Zeo (wt) selectable marker: *Sh ble* gene confers Zeocin™ resistance.

Elements for expression in mammalian cells

- Mammalian promoter combines the mouse CMV enhancer, the human elongation factor 1 alpha core promoter and 5'UTR containing a synthetic intron (SI 126).
- SV40 pAn: the Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA².

• MAR: Matrix attached regions (MARs) are sequences typically AT-rich that are able to form barriers between independently regulated domains³. This plasmid contains two MARs, from the 5' region of the human IFN-β gene and the β-globin gene. The MARs are placed between the bacterial and mammalian transcription units.

• MCS: The multiple cloning site contains several commonly used restriction sites for convenient cloning of a gene of interest.

5' Bsr GI, Stu I, Bgl II, Acc65 I, Asp 718, Eco O109I, Bsp 120I, Nhe I 3'

Due to the presence of the R6K origin of replication, pCpG plasmids can only be amplified in *E. coli* mutant strain expressing a *pir* mutant gene. They will not replicate in standard *E. coli* strains. Therefore, pCpG plasmids are provided with the *E. coli* GT115 strain, a *pir* mutant also deficient in *Dcm* methylation.

1. Wu F. *et al.* 1995. A DNA segment conferring stable maintenance on R6K gamma-origin core replicons. *J Bacteriol.* 177(22):6338-45. 2. Carswell S. & Alwine J.C., 1989. Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. *Mol. Cell Biol.* 10: 4248-4258. 3. Bode J. *et al.*, 1996. Scaffold/matrix-attached regions: topological switches with multiple regulatory functions. *Crit Rev Eukaryot Gene Expr.* 6(2-3):115-38.

METHODS

Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile H₂O. Store resuspended plasmid at -20 °C.

Reconstitution of *E. coli* GT115 strain

Use sterile conditions to do the following:

1. Reconstitute *E. coli* GT115 by adding 1 ml of Luria-Bertani (LB) medium in the tube containing the paper disk. Let sit for 5 minutes.
2. Mix gently by vortexing for 1-2 minutes.
3. Streak bacteria taken from this suspension on a LB agar plate.
4. Place the plate in an incubator at 37°C overnight.
5. Isolate a single colony and grow the bacteria in LB or terrific broth (TB) medium.
6. Prepare competent cells utilizing protocol of choice.

Plasmid amplification and cloning

Plasmid amplification and cloning can be performed in *E. coli* GT115.


Zeocin™ usage

This antibiotic can be used for *E. coli* at 25 µg/ml in liquid or solid media.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873
InvivoGen USA (International): +1 (858) 457-5873
InvivoGen Europe: +33 (0) 5-62-71-69-39
InvivoGen Hong Kong: +852 3-622-34-80
E-mail: info@invivogen.com





PacI (-1)

1 TTAATTAAAATTATCTCTAAGGCATGTGAACTGGCTGTCTTGGTTTTTCATCTGTACTTCATCTGCTACCTCTGTGACCTG

81 AAACATATTTATAATTCCATTAAGCTGTGCATATGATAGATTTATCATATGATTTTCCTTAAAGGATTTTTGTAAGAAC

161 TAATTGAATTGATACCTGTAAAGCTTTTATCACACTACCCAATAAATAAATCTCTTTGTTGAGCTCTCTGTTTCTAT

241 AAATATGTACCAGTTTTATTGTTTTTAGTGGTAGTGATTTTATTCTCTTTCTATATATACACACACATGTGTGCATTC

321 ATAAATATATACAATTTTTATGAATAAAAAATTATTAGCAATCAATATTGAAAACCACTGATTTTTGTTTATGTGAGCAA

SdaI (420)

EcoRI (415)

401 ACAGCAGATTA~~AAAAGGAATT~~CCTGCAGGAGATTGTACCTGCCCGTACATAAGGTCAATAGGGGGTGAATCAACAGGAAAG

481 TCCATTGGAGCCAAGTACACTGCGTCAATAGGGACTTTCCATTGGGTTTTGCCCGTACATAAGGTCAATAGGGGATGA

561 GTC AATGGGAAAAACCATTGGAGCCAAGTACACTGACTCAATAGGGACTTTCCATTGGGTTTTGCCCAGTACATAAGGT

641 CAATAGGGGGT GAGTCAACAGGAAAGTCCATTGGAGCCAAGTACATTGAGTCAATAGGGACTTTCCAATGGGTTTTGCC

721 CAGTACATAAGGTCAATGGGAGGTAAGCCAATGGGTTTTTCCATTACTGGCACGTATACTGAGTCATTAGGGACTTTCC

801 AATGGGTTTTGCCCAGTACATAAGGTCAATAGGGGTGAATCAACAGGAAAGTCCATTGGAGCCAAGTACACTGAGTCAA

881 TAGGGACTTTCCATTGGGTTTTGCCCAGTACAAAAGGTCAATAGGGGGTGAGTCAATGGGTTTTTCCATTATTGGCAGC

SpeI (981)

961 TACATAAGGTCAATAGGGGTGACTAGTCAGTGGGCAGAGCGCACATCGCCACAGTCCCGAGAAGTTGGGGGGAGGGGT

AgeI (1050)

1041 CGGCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTTC

1121 CCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTGGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACA

HindIII (1206)

1201 CAGCTGAAGCTTCTGCCTTCTCCCTCCTGTGAGTTTGgtaagtcactgactgtctatgcctgggaagggtgggcaggag

1281 atggggcagtcaggaaaagtggcactatgaaccTG CAGCCCTAGAcattgtactaaccttcttctcttctctctctct

Bsp120I (1408)

Asp718 (1400) **NheI (1417)**

BglIII (1393) **EcoO109I (1407)**

BsrGI (1370) **StuI (1386)** **Acc65I (1400)** **NcoI (1412)**

1361 gacagGTTGGTGTACAGTAGCTTCCAAGGCCTAAGATCTAGGTACCAAGGGCCCATGGCTAGCTGGCCAGACATGATAAG

1441 ATACATTGATGAGTTTGGACAAACCACAACCTAGAATGCAGTGAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTG

1521 CTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTT CAGGGG

EcoRI (1651)

1601 GAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTATGGAATTCAGTCAATATGTT CACCCCAAAA

1681 AGCTGTTTGTAACTTGCCAACCTCATTCTAAAATGTATATAGAAGCCCAAAAGACAATAACAAAAATATTCTGTAGAA

1761 CAAAATGGGAAAGAATGTTCCACTAAATATCAAGATTTAGAGCAAAGCATGAGATGTGTGGGGATAGACAGTGAGGCTGA

SacI (1852)

1841 TAAAATAGAGTAGAGCTCAGAAACAGACCCATTGATATATGTAAGTGACCTATGAAAAAATATGGCATTTTACAATGGG

1921 AAAATGATGGTCTTTTTCTTTTTTAGAAAAACAGGGAAATATATTTATATGAAAAAATAAAGGGAACCCATATGTCAT

2001 ACCATACACACAAAAAATTCCAGTGAATTATAAGTCTAAATGGAGAAGGCCAAAACCTTTAAATCTTTTAGAAAATAATAT

SphI (2084)

2081 AGAAGCATGCCATCAA GACTTCAGTGTAGAGAAAAATTTCTTATGACTCAAAGTCCTAACCACAAAGAAAAGATTGTTAA

2161 TTAGATTGCATGAATATTAAGACTTATTTTTAAAATTA AAAAACCTTAAGAAAAGTCAGGCCATAGAATGACAGAAAAT

2241 ATTTGCAACACCCCAGTAAAGAGAATTGTAATATGCAGATTATAAAAAGAAGTCTTACAAATCAGTAAAAATAAACTA

2321 GACAAAAATTTGAACAGATGAAAGAGAAAACCTAAATAATCATTACACATGAGAAAACCTCAATCTCAGAAATCAGAGAACT

PacI (2457)

2401 ATCATTGCATATACACTAAATTAGAGAAATATTA AAAAGGCTAAGTAACATCTGTGGCTTAATTA AAAATCTCGTAGCACGT

2481 GTCAGTCTGCTCCTCGGCCACGAAGTGCACGCAGTTGCCGGCCGGTTCGCGCAGGGCGAACTCCCGCCCCACGGTGC

125 • D Q E E A V F H V C N G A P D R L A F E R G W P Q

2561 TCGCCGATCTCGGTCATGGCCGGCCCGGAGGCGTCCCGGAAGTTCGTGGACACGACCTCCGACCACTCGGCGTACAGCTC

98 E G I E T M A P G S A D R F N T S V V E S W E A Y L E

2641 GTCCAGGCCGCGCACCCACACCCAGGCCAGGGTGTGTCCGGCACCACCTGGTCTGGACCGCGCTGATGAACAGGGTCA

72 D L G R V W V W A L T N D P V V Q D Q V A S I F L T V

SmaI (2762)

2721 CGTCGTCCCGGACCACACCGGCGAAGTCGTCCTCCACGAAGTCCCGGAGAACCCGAGCCGGTTCGGTCCAGA ACTCGACC

45 D D R V V G A F D D E V F D R S F G L R D T W F E V

NcoI (2852)

2801 GCTCCGGCGACGTCGCGCGCGGTGAGCACCGGAACGGCACTGGTCAACTTGGCCATGGTTTAGTTCCTCACCTTGTCGTA

18 A G A V D R A T L V P V A S T L K A M

AseI (2909)

PacI (2927)

2881 TTATACTATGCCGATATACTATGCCGATGATTAATTGTCAA CACGTGTTAATTAAGATCAGCAGTTCAACCTGTTGATAG

SnaBI (2960)

2961 TACGTAATAAGCTCTCATGTTTCACGTAATAAGCTCTCATGTTTAACGTAATAAGCTCTCATGTTTAACGAACTAAACCC

3041 TCATGGCTAACGTAATAAGCTCTCATGGCTAACGTAATAAGCTCTCATGTTTCACGTAATAAGCTCTCATGTTTGAACAA

AseI (3124)

3121 TAAAATTAATATAAATCAGCAACTTAAATAGCCTCTAAGGTTTTAAGTTTTATAAGAAAAAAGAATATATAAGGCTTT

HindIII (3202)

3201 TAAAGCTTTTAAGGTTTAACGGTTGTGGACAACAAGCCAGGGATGTAACGCACTGAGAAGCCCTTAGAGCCTCTCAAAGC

3281 AATTTTGAGTGACACAGGAACACTTAACGGCTGACAG